As the conditional registration of COVID-19 Vaccine Janssen has been approved, the company will continue to provide the results of ongoing clinical trials. This and other additional studies will provide information on how long protection against COVID-19 lasts, how well the vaccine protects against severe cases of COVID-19 and new strains of the virus, and how well it protects immuno-compromised patients, children, pregnant women and whether it prevents asymptomatic cases and the timing of a booster dose.
Furthermore, independent research into COVID-19 vaccines, coordinated by EU institutions, will also provide more information on the long-term safety and benefits of the vaccine for the public at large.